| Name | 1-[1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydropyrrolo[2,3-b]pyridin-4-yl]pyrazol-3-yl]imidazolidin-2-one |
|---|---|
| Synonyms |
unii-oj8eg4264p
emicerfont |
| Description | Emicerfont is a corticotropin-releasing factor type 1 (CRF1) receptor antagonist with an IC50 of 66 nM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 66 nM (CRF1 receptor)[1] |
| In Vitro | Emicerfont is a corticotropin-releasing factor type 1 (CRF1) receptor antagonist with an IC50 of 66 nM[1]. |
| In Vivo | At concentration of 10 mg/kg, Emicerfont reduces i.c.v. CRF-induced gerbil forepaw treading and marmoset defensive postures. Emicerfont also reduces rat pup ultrasonic vocalization at concentration of 30 mg/kg[1]. |
| References |
| Molecular Formula | C22H24N6O2 |
|---|---|
| Molecular Weight | 404.46500 |
| Exact Mass | 404.19600 |
| PSA | 79.01000 |
| LogP | 2.88650 |
| Storage condition | 2-8℃ |